Cardiol Therapeutics Inc. (CRDL.TO) TSX

Currency In CAD

Cardiol Therapeutics Inc.

Address

2265 Upper Middle Road East

Oakville, ON L6H 0G5

Canada

Phone

289 910 0850

Website

https://www.cardiolrx.com

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

First IPO Date

December 20, 2018

Key Executives

Name	Title	Pay	Year Born
David G. Elsley	President, Chief Executive Officer & Director	774,400	N/A
Christopher J. Waddick	Chief Financial Officer, Corporate Secretary & Director	303,600	N/A
Bernard Lim	Chief Operating Officer	531,300	N/A
Andrew Warwick Hamer	Chief Medical Officer and Head of Research & Development	801,662	1962
John A. Geddes BSCPT	Vice President of Corporate Development	0	N/A
Trevor Burns	Investor Relations	0	N/A

Description

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.